Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Garivulimab (Primary) ; Tislelizumab (Primary)
  • Indications Carcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 16 Feb 2023 Results of preliminary analysis assessing safety and efficacy of BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours published in the British Journal of Cancer
    • 12 Oct 2021 Primary end-points have been updated to change the timeframe from 3 years to 33.5 months and Number of Participants With Abnormal Electrocardiograms (ECG), Number of Participants With Abnormalities During Physical Examinations and Number of Participants With Abnormal Lab Assessment Results have been added as new primary end points. Time frame for RP2D is changed from 3 years to 28 months.
    • 06 May 2021 Status changed from active, no longer recruiting to discontinued and terminated early.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top